PSMA PET scans to check for returning prostate cancer after focused ultrasound treatment
Tests PSMA PET scans for finding prostate cancer after HIFU treatment.
Plain-language title generated from the registry record
Registry title: Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
Key facts
- Where
- Toulouse, FranceSee the site
- Phase
- Phase 4
Where in France
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT07766122EU 2026-525181-22-00
- Record updated
- 5 November 2026
- Original description
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI in detecting clinically significant recurrent PaC after treatment with HIFU. The main objective was to evaluate the diagnostic performance of PSMA PET compared with MRI with reference to the gold standard of prostate biopsy one year after HIFU.Read full original descriptionShow less
Pilot Study Evaluating PSMA Positron Emission Tomography for Monitoring Clinically Significant Prostate Cancer After Focal HIFU Treatment
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI in detecting clinically significant recurrent PaC after treatment with HIFU. The main objective was to evaluate the diagnostic performance of PSMA PET compared with MRI with reference to the gold standard of prostate biopsy one year after HIFU.
Inclusion: Patient with prostate cancer; Age ≥ 70 years (HAS 2023); Life expectancy > 5 years; Clinical stage Clinical stage T1c - T2a PSA < 20 ng/ml Biopsy :ISUP 2 unilateral on a maximum of 2 contiguous sextants with or without ipsilateral or contralateral focus ISUP1 single focus or multiple foci if only one ISUP 2 focus on targeted biopsy; Imaging Single lesion PIRADS 3 or 4 or 5 Volume of prostate gland < 150 ml; Enrolled in a social security scheme; Signature of consent.
Exclusion: Any condition that, in the judgement of the investigators, would interfere with the subject's ability to; Hypersensitivity to the active substances or to any of the excipients; Conditions contraindicating magnetic resonance imaging (MRI), such as the presence of internal metallic devices; Liver failure; Chronic kidney disease with an eGFR ≤ 60 mL/min; Evidence of extra-prostatic extension or invasion of the seminal vesicles; provide informed consent, comply with study instructions, expose the subject to increased risk, or interfere with the interpretation of study results; Patients deprived of their liberty or under legal protection (curatorship and guardianship, safeguard of justice).